Familial Hypercholesterolemia: Where Do We Stand?

Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):

Share this content! On (X network) By

Familial Hypercholesterolemia: Where Do We Stand? Publisher

Abhari AP¹ ; Karami D¹ ; Adelparvar F¹ ; Sadeghi M²

Show Affiliations

1. Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran
2. Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran

Source: ARYA Atherosclerosis Published:2023

Abstract

[No abstract available]

Related Docs

1. Familial Hypercholesterolemia (Fh) Registry Worldwide: A Systematic Review, Current Problems in Cardiology (2022)

Experts (# of related papers)

View all Related Experts

Nizal Sarrafzadegan (1)

Golnaz Vaseghi (1)

Style	Citing Format
MLA	Abhari AP, et al.. "Familial Hypercholesterolemia: Where Do We Stand?." ARYA Atherosclerosis, vol. 19, no. 3, 2023, pp. 59-61.
APA	Abhari AP, Karami D, Adelparvar F, Sadeghi M (2023). Familial Hypercholesterolemia: Where Do We Stand?. ARYA Atherosclerosis, 19(3), 59-61.
Chicago	Abhari AP, Karami D, Adelparvar F, Sadeghi M. "Familial Hypercholesterolemia: Where Do We Stand?." ARYA Atherosclerosis 19, no. 3 (2023): 59-61.
Harvard	Abhari AP et al. (2023) 'Familial Hypercholesterolemia: Where Do We Stand?', ARYA Atherosclerosis, 19(3), pp. 59-61.
Vancouver	Abhari AP, Karami D, Adelparvar F, Sadeghi M. Familial Hypercholesterolemia: Where Do We Stand?. ARYA Atherosclerosis. 2023;19(3):59-61.
BibTex	@article{ author = {Abhari AP and Karami D and Adelparvar F and Sadeghi M}, title = {Familial Hypercholesterolemia: Where Do We Stand?}, journal = {ARYA Atherosclerosis}, volume = {19}, number = {3}, pages = {59-61}, year = {2023} }
RIS	TY - JOUR AU - Abhari AP AU - Karami D AU - Adelparvar F AU - Sadeghi M TI - Familial Hypercholesterolemia: Where Do We Stand? JO - ARYA Atherosclerosis VL - 19 IS - 3 SP - 59 EP - 61 PY - 2023 ER -